Zinforo (ceftaroline fosamil)
- Region
- 🇪🇺 EU
- Active substance
- ceftaroline fosamil
- Company
- Pfizer Ireland Pharmaceuticals
- Status
- Authorised
- Therapeutic area
- Community-Acquired Infections; Skin Diseases, Infectious; Pneumonia
- CHMP opinion
- Thu 21 Jun 2012
- EU approval
- Wed 22 Aug 2012
- Application
- EMEA/H/C/002252
- ATC
- J01DI02
- Official record
- www.ema.europa.eu
Indication
Zinforo is indicated for the treatment of the following infections in neonates, infants, children, adolescents and adults: Complicated skin and soft tissue infections (cSSTI) Community-acquired pneumonia (CAP) Consideration should be given to official guidance on the appropriate use of antibacterial agents.
Regulatory milestones
No milestones recorded in the last year.
Follow Zinforo
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.